Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Ascendis Pharma A (ASND) over the last 8 years, with Q4 2025 value amounting to $446.8 million.

  • Ascendis Pharma A's Other Accumulated Expenses rose 3983.45% to $446.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $446.8 million, marking a year-over-year increase of 3983.45%. This contributed to the annual value of $433.7 million for FY2025, which is 3574.49% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Other Accumulated Expenses of $446.8 million as of Q4 2025, which was up 3983.45% from $381.7 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Other Accumulated Expenses ranged from a high of $446.8 million in Q4 2025 and a low of $13.6 million during Q1 2021
  • For the 4-year period, Ascendis Pharma A's Other Accumulated Expenses averaged around $234.3 million, with its median value being $273.7 million (2024).
  • Data for Ascendis Pharma A's Other Accumulated Expenses shows a peak YoY increase of 6713.17% (in 2021) and a maximum YoY decrease of 2552.43% (in 2021) over the last 5 years.
  • Ascendis Pharma A's Other Accumulated Expenses (Quarter) stood at $38.2 million in 2021, then soared by 424.71% to $200.3 million in 2023, then skyrocketed by 59.55% to $319.5 million in 2024, then soared by 39.83% to $446.8 million in 2025.
  • Its Other Accumulated Expenses stands at $446.8 million for Q4 2025, versus $381.7 million for Q3 2025 and $373.9 million for Q2 2025.